Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/dGzwCrsecruLryBJgdzS?format=wireless

  ADVERTISEMENT  
June 12, 2012
  ADVERTISEMENT  
News for diabetes health professionals
Sign up|Forward|Archive|Advertise

Diabetes in Focus 
  • Prediabetes treatment can prevent progression to diabetes
    Prediabetes patients who were able to return to normal blood glucose levels, even for a short time and regardless of techniques used, were 56% less likely to develop full-blown type 2 diabetes in nearly six years of follow-up, a study presented at the ADA 72nd Scientific Sessions showed. The findings were published in The Lancet. HealthDay News (6/11) LinkedInFacebookTwitterEmail this Story
  • Some diabetes drugs raise macular edema risk, study finds
    Type 2 diabetes patients who use thiazolidinediones such as Avandia and Actos are at two to three times higher risk of developing macular edema than nonusers, according to a study in the Archives of Internal Medicine. "More aggressive management of risk factors for macular edema should be implemented in patients who take thiazolidinedione," lead researcher Dr. Iskandar Idris said. "In addition, routine screening for visual acuity should be performed during routine diabetes review, especially for patients who take thiazolidinediones." HealthDay News (6/11) LinkedInFacebookTwitterEmail this Story
  • Fast glucose uptick raises treatment failure in young diabetes patients
    A rapid increase in baseline A1C levels after initial stabilization elevates the risk of treatment failure in children with type 2 diabetes, suggesting that more intensive treatment may be needed, a study presented at the ADA 72nd Scientific Sessions found. "We need to identify specific thresholds for intensifying therapy, perhaps at diagnosis, perhaps after a certain period of treatment, or when the patient reaches a certain HbA1c threshold," researcher Dr. Sonia Caprio said. Family Practice News (6/11) LinkedInFacebookTwitterEmail this Story
  • Study: Exenatide better than glimepiride as second-line therapy
    Among patients with type 2 diabetes not controlled by metformin, fewer experienced treatment failure with twice-daily exenatide than with once-daily glimepiride, according to a study presented at the ADA 72nd Scientific Sessions and published in The Lancet. Researchers also noted lower blood glucose levels and greater weight loss in the exenatide group than the glimepiride group. Endocrine Today (6/10) LinkedInFacebookTwitterEmail this Story
  • Strategies targeting health care system show blood glucose benefits
    The use of quality improvement strategies -- including team changes, case management, patient education and self-management promotion -- helped reduce blood glucose levels and improved cardiovascular risk factors in diabetes patients after a one-year follow-up, a meta-analysis revealed. QI strategies that dealt with the entire chronic disease management system had the biggest impacts regardless of baseline A1C rates, researchers said. The results were presented at the ADA 72nd Scientific Sessions and published in The Lancet. MedPage Today (free registration) (6/9) LinkedInFacebookTwitterEmail this Story
  ADVERTISEMENT  
Support DiabetesPro SmartBrief
DiabetesPro SmartBrief is the daily e-news resource for 29,000 influential leaders in diabetes care. E-mail Aaron Kern for more information on advertising.

Nutrition & Wellness 
  • Poll: 64% are against NYC plan to restrict beverage sizes
    An American Mosaic Reuters/Ipsos poll indicates that 64% of Americans say they'd oppose a plan similar to one in New York City to limit serving sizes of sugary drinks. More than 70% said such a measure would not reduce obesity rates, and people who opposed the idea felt it would give the government too much control over their dietary choices. Reuters (6/8) LinkedInFacebookTwitterEmail this Story
Practice Update 
  • Study examines physicians' tech use
    Eighty-one percent of physicians surveyed used a portable device to access the Internet in the last six months, while 59% used social networking sites and 49% used e-mail to communicate with their patients, a study in the Journal of the American Medical Informatics Association revealed. The results show that demographic characteristics, and not specialty or practice setting, were more consistent predictors of technology use among physicians. American Medical News (free content) (6/11) LinkedInFacebookTwitterEmail this Story
Trends & Technology 
  • Combined EHRs help identify 1.1M people with diabetes
    Researchers detected nearly 1.1 million individuals with diabetes after examining 15.8 million EHRs from 11 integrated health plans and used those EHRs to create a database registry, called Surveillance, Prevention and Management of Diabetes Mellitus DataLink. The registry is one aspect of an overall information-sharing initiative called Virtual Data Warehouse that is supported by an Agency for Healthcare Research and Quality grant. Modern Healthcare (subscription required) (6/8) LinkedInFacebookTwitterEmail this Story
ADA Scientific Sessions 
  • Latest abstracts to close out scientific sessions
    The most up-to-date advances in diabetes research will be featured in the Late Breaking Abstracts session, which will close out this year's ADA 72nd Scientific Sessions. Presentations will focus on abstracts submitted to the ADA in late April and early May and include "a very interesting balance between basic science and clinical trials," according to Dr. Robert E. Ratner, ADA Chief Scientific and Medical Officer. ADA Diabetes Dispatch (2012) LinkedInFacebookTwitterEmail this Story
Conference Information 
  • Meeting updates and highlights
    The 72nd Scientific Sessions website will include a page listing program updates and changes as they happen. The page will also include daily meeting highlights and events. Learn more. LinkedInFacebookTwitterEmail this Story
  • Get the 72nd Scientific Sessions App!
    Planning your time at the Scientific Sessions is only a click away with the on-the-go Scientific Sessions App! This application gives direct and instant access to meeting information from your smartphone, tablet or other handheld device. Features include interactive program and course schedules, customizable calendar and itinerary builder, exhibitor listing with interactive booth map, social media interaction and special meeting alerts. Learn more. LinkedInFacebookTwitterEmail this Story
  • CME/CE Credit for the 72nd Scientific Sessions
    Don't forget to visit scientificsessions.diabetes.org to obtain CME/CE credit for the meeting! The online system is available through July 13. LinkedInFacebookTwitterEmail this Story
SmartQuote 
Be brave enough to live creatively."
--Alan Alda,
American actor
LinkedInFacebookTwitterEmail this Story

  

Product announcements appearing in SmartBrief are paid advertisements and do not reflect actual DiabetesPro endorsements. The news reported in SmartBrief does not necessarily reflect the official position of DiabetesPro.
 
Subscriber Tools
   
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Advertise
Account Director: Aaron Kern (202) 407-7866
 
Read more at SmartBrief.com
 
 
 Recent DiabetesPro SmartBrief Issues:   Editor: Kathryn Doherty

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2014 SmartBrief, Inc.® Legal Information